WSI Co

WSI Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of WSI Co (299170.KQ) as of Oct 16, 2026 is -56.74 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 494.79 % — a change of -111.47% (lower).

FCF Conversion

-56.74 %

YoY

-111.47%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of WSI Co is 2025 -56.74 % . FCF Conversion Rate (FCF/EBITDA) of WSI Co was 2024 494.79 % . It decreases by -111.47% lower compared to the previous year.

The WSI Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
177.98 KRW
Jan 1, 2019
4,604.67 KRW
Jan 1, 2020
18.26 KRW
Jan 1, 2021
30.67 KRW
Jan 1, 2022
-132.51 KRW
Jan 1, 2023
-338.87 KRW
Jan 1, 2024
494.79 KRW
Jan 1, 2025
-56.74 KRW
The WSI Co FCF Conversion history
YEARFCF ConversionYoY
-56.74 %-111.47%
494.79 %-246.01%
-338.87 %+155.73%
-132.51 %-532.05%
30.67 %+67.94%
18.26 %-99.60%
4,604.67 %+2,487.18%
177.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

WSI Co Stock analysis

What does WSI Co do? WSI Co Ltd is a South Korean company operating in the health care sector, headquartered in Seoul. The company went public on September 21, 2018, with a ticker symbol of 299170.KQ and ISIN KR7299170001. WSI Co Ltd manufactures medical devices and pharmaceutical products, focusing on specific therapeutic areas. The company distributes a topical hemostatic agent called Flosils. It also supplies endoscopes used in spinal surgery, anti-adhesion agents, and bone hemostatic agents. WSI Co Ltd's business activities are centered around medical devices and pharmaceuticals, with an emphasis on products that address hemostasis and surgical procedures. The company's website is https://wsi-healthcare.com/, where further information about its products and services may be found. As a publicly listed company, WSI Co Ltd operates within the South Korean financial market and serves customers primarily in the health care industry. The company's product portfolio includes both medical devices and pharmaceuticals, targeting specific clinical applications such as surgical hemostasis and spinal procedures. There is no indication of additional product lines or services beyond those mentioned in the source description. The company's operations are based in Seoul, South Korea, and it has been publicly traded since 2018. WSI Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about WSI Co stock

FCF Conversion Rate (FCF/EBITDA) of WSI Co is -56.74 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of WSI Co changed from 494.79 % to -56.74 %, representing a -111.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) WSI Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s WSI Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — WSI Co

All Key Metrics — WSI Co